-+ 0.00%
-+ 0.00%
-+ 0.00%

Tiziana Life Sciences Executive Chairman Gabriele Cerrone Acquires 97,687 Company Common Shares

Benzinga·12/19/2025 16:02:48
Listen to the news

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 97,687 common shares, bringing his total holding to 43,374,830 common shares, which is 36.08% of issued share capital.